Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy

Patients with DLBCL achieving complete metabolic response (CMR) after initial treatment with R-CHOP generally have a favourable prognosis; however, there are no established prognostic biomarkers for relapse in these patients. Soluble interleukin-2 receptor (sIL-2R) levels at diagnosis are prognostic...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2023-08, Vol.13 (1), p.13713-13713, Article 13713
Main Authors: Shirouchi, Yuko, Nishimura, Noriko, Mishima, Yuko, Ishihara, Yuko, Asai, Hiroaki, Tamba, Mikako, Hirano, Mitsuhito, Hirano, Kei, Teramoto, Yukako, Yoshida, Kikuaki, Takeuchi, Kengo, Terauchi, Takashi, Maruyama, Dai
Format: Article
Language:English
Subjects:
631/67/1990
631/67/1990/291
631/67/1990/291/1621
631/67/1990/291/1621/1915
B-cell lymphoma
Cytokines
Humanities and Social Sciences
Interleukin 2
Lymphocytes B
Lymphoma
Medical prognosis
Metabolic response
Metabolism
multidisciplinary
Science
Science (multidisciplinary)
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c584t-8337a065fe97b0e09fb5c62fc056b630eb012e981cc970f21df07bc0c48680c13
cites cdi_FETCH-LOGICAL-c584t-8337a065fe97b0e09fb5c62fc056b630eb012e981cc970f21df07bc0c48680c13
container_end_page 13713
container_issue 1
container_start_page 13713
container_title Scientific reports
container_volume 13
creator Shirouchi, Yuko
Nishimura, Noriko
Mishima, Yuko
Ishihara, Yuko
Asai, Hiroaki
Tamba, Mikako
Hirano, Mitsuhito
Hirano, Kei
Teramoto, Yukako
Yoshida, Kikuaki
Takeuchi, Kengo
Terauchi, Takashi
Maruyama, Dai
description Patients with DLBCL achieving complete metabolic response (CMR) after initial treatment with R-CHOP generally have a favourable prognosis; however, there are no established prognostic biomarkers for relapse in these patients. Soluble interleukin-2 receptor (sIL-2R) levels at diagnosis are prognostic factors in patients with DLBCL. However, the significance of post-treatment sIL-2R levels is unclear. To determine the significance of post-treatment serum sIL-2R levels on subsequent relapse and survival, we retrospectively analysed 485 patients with newly diagnosed DLBCL who received R-CHOP treatment and achieved CMR. The cumulative incidence of relapse (CIR) was significantly higher in patients with elevated post-treatment sIL-2R levels than in those with normal sIL-2R levels (five-year CIR; 38.8% vs. 12.8%). The prognostic value remained significant in multivariable analysis (hazard ratio, 2.30; p  
doi_str_mv 10.1038/s41598-023-40026-7
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e8e748f702c940529d35c0322c9a92dd</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_e8e748f702c940529d35c0322c9a92dd</doaj_id><sourcerecordid>2854688878</sourcerecordid><originalsourceid>FETCH-LOGICAL-c584t-8337a065fe97b0e09fb5c62fc056b630eb012e981cc970f21df07bc0c48680c13</originalsourceid><addsrcrecordid>eNp9ksFu1DAQhiMEolXpC3CyxIVLYOI4iX1CsAJaqVIrBGfLccbZLE4cbGdX-3y8GE63AsoBX2yP___T6Pdk2csC3hRQ8reBFZXgOdAyZwC0zpsn2TkFVuW0pPTpX-ez7DKEHaRVUcEK8Tw7K5saOFBxnv28866fXIiDJntlFyTOkDnd8-hRxRGnSAL6ZSTB2aW1SIYpore4fB-mnBKPGufofCqTCQ_2SLpBrUDs0smYJSCxyvdIPuQarSX2OM5bNyoyqzgkeiCHrSNKbwfcJ49242wxIhkxqtbZ1JbHMLspcYyz1h2GqSdf8s3V7R2JW_RqPr7InhllA14-7BfZt08fv26u8pvbz9eb9ze5rjiLOS_LRkFdGRRNCwjCtJWuqdFQ1W1dArZQUBS80Fo0YGjRGWhaDZrxmoMuyovs-sTtnNrJ2Q-j8kfp1CDvC873UvkUpEWJHBvGTQNUC7bm3pWVhvQZWihBuy6x3p1Y89KO2OmUhFf2EfTxyzRsZe_2sgDGWCPWbl4_ELz7sWCIchzCGrGa0C1BUl7VZcFFTZP01T_SnVv8lLJaVazmnDc8qehJpb0LwaP53U0Bcp05eZo5mWZO3s-cbJKpPJlCEk89-j_o_7h-AZLY3Iw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2854688878</pqid></control><display><type>article</type><title>Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy</title><source>Open Access: PubMed Central</source><source>ProQuest - Publicly Available Content Database</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Shirouchi, Yuko ; Nishimura, Noriko ; Mishima, Yuko ; Ishihara, Yuko ; Asai, Hiroaki ; Tamba, Mikako ; Hirano, Mitsuhito ; Hirano, Kei ; Teramoto, Yukako ; Yoshida, Kikuaki ; Takeuchi, Kengo ; Terauchi, Takashi ; Maruyama, Dai</creator><creatorcontrib>Shirouchi, Yuko ; Nishimura, Noriko ; Mishima, Yuko ; Ishihara, Yuko ; Asai, Hiroaki ; Tamba, Mikako ; Hirano, Mitsuhito ; Hirano, Kei ; Teramoto, Yukako ; Yoshida, Kikuaki ; Takeuchi, Kengo ; Terauchi, Takashi ; Maruyama, Dai</creatorcontrib><description>Patients with DLBCL achieving complete metabolic response (CMR) after initial treatment with R-CHOP generally have a favourable prognosis; however, there are no established prognostic biomarkers for relapse in these patients. Soluble interleukin-2 receptor (sIL-2R) levels at diagnosis are prognostic factors in patients with DLBCL. However, the significance of post-treatment sIL-2R levels is unclear. To determine the significance of post-treatment serum sIL-2R levels on subsequent relapse and survival, we retrospectively analysed 485 patients with newly diagnosed DLBCL who received R-CHOP treatment and achieved CMR. The cumulative incidence of relapse (CIR) was significantly higher in patients with elevated post-treatment sIL-2R levels than in those with normal sIL-2R levels (five-year CIR; 38.8% vs. 12.8%). The prognostic value remained significant in multivariable analysis (hazard ratio, 2.30; p  &lt; 0.001). Five-year progression-free survival (49.0% vs. 83.5%) and overall survival (61.7% vs. 91.6%) rates were lower in patients with elevated post-treatment sIL-2R levels than in those with normal sIL-2R levels ( p  &lt; 0.001 for both). In patients with newly diagnosed DLBCL who achieved CMR after R-CHOP treatment, the post-treatment serum sIL-2R level was an independent prognostic marker of subsequent relapse and survival.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-023-40026-7</identifier><identifier>PMID: 37608029</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/1990 ; 631/67/1990/291 ; 631/67/1990/291/1621 ; 631/67/1990/291/1621/1915 ; B-cell lymphoma ; Cytokines ; Humanities and Social Sciences ; Interleukin 2 ; Lymphocytes B ; Lymphoma ; Medical prognosis ; Metabolic response ; Metabolism ; multidisciplinary ; Science ; Science (multidisciplinary) ; Survival</subject><ispartof>Scientific reports, 2023-08, Vol.13 (1), p.13713-13713, Article 13713</ispartof><rights>The Author(s) 2023</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Springer Nature Limited 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c584t-8337a065fe97b0e09fb5c62fc056b630eb012e981cc970f21df07bc0c48680c13</citedby><cites>FETCH-LOGICAL-c584t-8337a065fe97b0e09fb5c62fc056b630eb012e981cc970f21df07bc0c48680c13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2854688878/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2854688878?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids></links><search><creatorcontrib>Shirouchi, Yuko</creatorcontrib><creatorcontrib>Nishimura, Noriko</creatorcontrib><creatorcontrib>Mishima, Yuko</creatorcontrib><creatorcontrib>Ishihara, Yuko</creatorcontrib><creatorcontrib>Asai, Hiroaki</creatorcontrib><creatorcontrib>Tamba, Mikako</creatorcontrib><creatorcontrib>Hirano, Mitsuhito</creatorcontrib><creatorcontrib>Hirano, Kei</creatorcontrib><creatorcontrib>Teramoto, Yukako</creatorcontrib><creatorcontrib>Yoshida, Kikuaki</creatorcontrib><creatorcontrib>Takeuchi, Kengo</creatorcontrib><creatorcontrib>Terauchi, Takashi</creatorcontrib><creatorcontrib>Maruyama, Dai</creatorcontrib><title>Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><description>Patients with DLBCL achieving complete metabolic response (CMR) after initial treatment with R-CHOP generally have a favourable prognosis; however, there are no established prognostic biomarkers for relapse in these patients. Soluble interleukin-2 receptor (sIL-2R) levels at diagnosis are prognostic factors in patients with DLBCL. However, the significance of post-treatment sIL-2R levels is unclear. To determine the significance of post-treatment serum sIL-2R levels on subsequent relapse and survival, we retrospectively analysed 485 patients with newly diagnosed DLBCL who received R-CHOP treatment and achieved CMR. The cumulative incidence of relapse (CIR) was significantly higher in patients with elevated post-treatment sIL-2R levels than in those with normal sIL-2R levels (five-year CIR; 38.8% vs. 12.8%). The prognostic value remained significant in multivariable analysis (hazard ratio, 2.30; p  &lt; 0.001). Five-year progression-free survival (49.0% vs. 83.5%) and overall survival (61.7% vs. 91.6%) rates were lower in patients with elevated post-treatment sIL-2R levels than in those with normal sIL-2R levels ( p  &lt; 0.001 for both). In patients with newly diagnosed DLBCL who achieved CMR after R-CHOP treatment, the post-treatment serum sIL-2R level was an independent prognostic marker of subsequent relapse and survival.</description><subject>631/67/1990</subject><subject>631/67/1990/291</subject><subject>631/67/1990/291/1621</subject><subject>631/67/1990/291/1621/1915</subject><subject>B-cell lymphoma</subject><subject>Cytokines</subject><subject>Humanities and Social Sciences</subject><subject>Interleukin 2</subject><subject>Lymphocytes B</subject><subject>Lymphoma</subject><subject>Medical prognosis</subject><subject>Metabolic response</subject><subject>Metabolism</subject><subject>multidisciplinary</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Survival</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9ksFu1DAQhiMEolXpC3CyxIVLYOI4iX1CsAJaqVIrBGfLccbZLE4cbGdX-3y8GE63AsoBX2yP___T6Pdk2csC3hRQ8reBFZXgOdAyZwC0zpsn2TkFVuW0pPTpX-ez7DKEHaRVUcEK8Tw7K5saOFBxnv28866fXIiDJntlFyTOkDnd8-hRxRGnSAL6ZSTB2aW1SIYpore4fB-mnBKPGufofCqTCQ_2SLpBrUDs0smYJSCxyvdIPuQarSX2OM5bNyoyqzgkeiCHrSNKbwfcJ49242wxIhkxqtbZ1JbHMLspcYyz1h2GqSdf8s3V7R2JW_RqPr7InhllA14-7BfZt08fv26u8pvbz9eb9ze5rjiLOS_LRkFdGRRNCwjCtJWuqdFQ1W1dArZQUBS80Fo0YGjRGWhaDZrxmoMuyovs-sTtnNrJ2Q-j8kfp1CDvC873UvkUpEWJHBvGTQNUC7bm3pWVhvQZWihBuy6x3p1Y89KO2OmUhFf2EfTxyzRsZe_2sgDGWCPWbl4_ELz7sWCIchzCGrGa0C1BUl7VZcFFTZP01T_SnVv8lLJaVazmnDc8qehJpb0LwaP53U0Bcp05eZo5mWZO3s-cbJKpPJlCEk89-j_o_7h-AZLY3Iw</recordid><startdate>20230822</startdate><enddate>20230822</enddate><creator>Shirouchi, Yuko</creator><creator>Nishimura, Noriko</creator><creator>Mishima, Yuko</creator><creator>Ishihara, Yuko</creator><creator>Asai, Hiroaki</creator><creator>Tamba, Mikako</creator><creator>Hirano, Mitsuhito</creator><creator>Hirano, Kei</creator><creator>Teramoto, Yukako</creator><creator>Yoshida, Kikuaki</creator><creator>Takeuchi, Kengo</creator><creator>Terauchi, Takashi</creator><creator>Maruyama, Dai</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230822</creationdate><title>Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy</title><author>Shirouchi, Yuko ; Nishimura, Noriko ; Mishima, Yuko ; Ishihara, Yuko ; Asai, Hiroaki ; Tamba, Mikako ; Hirano, Mitsuhito ; Hirano, Kei ; Teramoto, Yukako ; Yoshida, Kikuaki ; Takeuchi, Kengo ; Terauchi, Takashi ; Maruyama, Dai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c584t-8337a065fe97b0e09fb5c62fc056b630eb012e981cc970f21df07bc0c48680c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>631/67/1990</topic><topic>631/67/1990/291</topic><topic>631/67/1990/291/1621</topic><topic>631/67/1990/291/1621/1915</topic><topic>B-cell lymphoma</topic><topic>Cytokines</topic><topic>Humanities and Social Sciences</topic><topic>Interleukin 2</topic><topic>Lymphocytes B</topic><topic>Lymphoma</topic><topic>Medical prognosis</topic><topic>Metabolic response</topic><topic>Metabolism</topic><topic>multidisciplinary</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shirouchi, Yuko</creatorcontrib><creatorcontrib>Nishimura, Noriko</creatorcontrib><creatorcontrib>Mishima, Yuko</creatorcontrib><creatorcontrib>Ishihara, Yuko</creatorcontrib><creatorcontrib>Asai, Hiroaki</creatorcontrib><creatorcontrib>Tamba, Mikako</creatorcontrib><creatorcontrib>Hirano, Mitsuhito</creatorcontrib><creatorcontrib>Hirano, Kei</creatorcontrib><creatorcontrib>Teramoto, Yukako</creatorcontrib><creatorcontrib>Yoshida, Kikuaki</creatorcontrib><creatorcontrib>Takeuchi, Kengo</creatorcontrib><creatorcontrib>Terauchi, Takashi</creatorcontrib><creatorcontrib>Maruyama, Dai</creatorcontrib><collection>SpringerOpen(OpenAccess)</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shirouchi, Yuko</au><au>Nishimura, Noriko</au><au>Mishima, Yuko</au><au>Ishihara, Yuko</au><au>Asai, Hiroaki</au><au>Tamba, Mikako</au><au>Hirano, Mitsuhito</au><au>Hirano, Kei</au><au>Teramoto, Yukako</au><au>Yoshida, Kikuaki</au><au>Takeuchi, Kengo</au><au>Terauchi, Takashi</au><au>Maruyama, Dai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><date>2023-08-22</date><risdate>2023</risdate><volume>13</volume><issue>1</issue><spage>13713</spage><epage>13713</epage><pages>13713-13713</pages><artnum>13713</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Patients with DLBCL achieving complete metabolic response (CMR) after initial treatment with R-CHOP generally have a favourable prognosis; however, there are no established prognostic biomarkers for relapse in these patients. Soluble interleukin-2 receptor (sIL-2R) levels at diagnosis are prognostic factors in patients with DLBCL. However, the significance of post-treatment sIL-2R levels is unclear. To determine the significance of post-treatment serum sIL-2R levels on subsequent relapse and survival, we retrospectively analysed 485 patients with newly diagnosed DLBCL who received R-CHOP treatment and achieved CMR. The cumulative incidence of relapse (CIR) was significantly higher in patients with elevated post-treatment sIL-2R levels than in those with normal sIL-2R levels (five-year CIR; 38.8% vs. 12.8%). The prognostic value remained significant in multivariable analysis (hazard ratio, 2.30; p  &lt; 0.001). Five-year progression-free survival (49.0% vs. 83.5%) and overall survival (61.7% vs. 91.6%) rates were lower in patients with elevated post-treatment sIL-2R levels than in those with normal sIL-2R levels ( p  &lt; 0.001 for both). In patients with newly diagnosed DLBCL who achieved CMR after R-CHOP treatment, the post-treatment serum sIL-2R level was an independent prognostic marker of subsequent relapse and survival.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>37608029</pmid><doi>10.1038/s41598-023-40026-7</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2045-2322
ispartof Scientific reports, 2023-08, Vol.13 (1), p.13713-13713, Article 13713
issn 2045-2322
2045-2322
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_e8e748f702c940529d35c0322c9a92dd
source Open Access: PubMed Central; ProQuest - Publicly Available Content Database; Free Full-Text Journals in Chemistry; Springer Nature - nature.com Journals - Fully Open Access
subjects 631/67/1990
631/67/1990/291
631/67/1990/291/1621
631/67/1990/291/1621/1915
B-cell lymphoma
Cytokines
Humanities and Social Sciences
Interleukin 2
Lymphocytes B
Lymphoma
Medical prognosis
Metabolic response
Metabolism
multidisciplinary
Science
Science (multidisciplinary)
Survival
title Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T10%3A23%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20post-treatment%20serum%20soluble%20interleukin-2%20receptor%20in%20newly%20diagnosed%20diffuse%20large%20B-cell%20lymphoma%20patients%20who%20achieved%20complete%20metabolic%20response%20following%20R-CHOP%20therapy&rft.jtitle=Scientific%20reports&rft.au=Shirouchi,%20Yuko&rft.date=2023-08-22&rft.volume=13&rft.issue=1&rft.spage=13713&rft.epage=13713&rft.pages=13713-13713&rft.artnum=13713&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-023-40026-7&rft_dat=%3Cproquest_doaj_%3E2854688878%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c584t-8337a065fe97b0e09fb5c62fc056b630eb012e981cc970f21df07bc0c48680c13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2854688878&rft_id=info:pmid/37608029&rfr_iscdi=true